ALKS News and Press, Alkermes plc From 05/01/24

2024-05-01 11:20:07 ET Alkermes plc (ALKS) Q1 2024 Earnings Conference Call May 01, 2024 08:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Blair Jackson - Chief Operating Officer Todd Nichols - Chief ...

2024-05-01 07:07:03 ET More on Alkermes Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data Alkermes plc: Collecting The Fruits Of The 2023 Spinoff Alkermes plc 2023 Q4 - Results - Earnings Call Presentation Alkermes Q1 2024 Earnings Preview ...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

2024-04-30 11:51:08 ET More on Alkermes Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data Alkermes plc: Collecting The Fruits Of The 2023 Spinoff Alkermes plc 2023 Q4 - Results - Earnings Call Presentation Alkermes posts early-stage win for s...

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a pha...

Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Ma...

2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...

2024-04-10 09:00:04 ET Akash Tewari from Jefferies issued a price target of $50.00 for ALKS on 2024-04-10 07:44:00. The adjusted price target was set to $50.00. At the time of the announcement, ALKS was trading at $26.73. The overall price target consensus is at $31.33 w...

2024-04-09 16:29:10 ET Summary Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this y...

2024-04-09 15:15:03 ET UBS analyst issues BUY recommendation for ALKS on April 9, 2024 01:01PM ET. The previous analyst recommendation was Buy. ALKS was trading at $26.765 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst r...